Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 1

Trials using Anti-EGFR mABs for chemotherapy-resistant mCRC not selected by KRAS status.

Trial (author)	Phase	Protocol	Number enrolled	Results		HR (95% CI)	𝑃 value
				PFS	OS
— (Saltz et al.) [7]	II	Cetuximab	57	PR 9%
CO.17 (Jonker et al.) [8]	III	Cetuximab; BSC	287; 285		6.1 mos.; 4.6 mos.	OS: 0.77 (0.64–0.92)	<0.005
— (Peeters et al.) [9]	III	Panitumumab + BSC; BSC	231; 232	8 wks.; 7.3 wks.		PFS: 0.54 (0.44–0.66)	<0.0001
BOND (Cunningham; et al.) [10]	II	Cetuximab + irinotecan	218	PR 22.9%		PR: N/A	<0.001
		cetuximab	211	PR 10.8%
EPIC (Sobrero et al.) [11]	III	Cetuximab + Irinotecan	648	4.0 mos.	10.7 mos.	PFS: 0.69 (0.61–0.77); OS: 0.97 (0.84–1.11); RR: N/A	<0.0001; 0.71; <0.0001
				RR 16.4%
		Irinotecan	650	2.6 mos.	10.0 mos.
				RR 4.2%

BSC: best supportive care, PR: partial response, OS: overall survival, PFS: progression-free survival, RR: response rate, and N/A: not applicable.